# Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Study · id `cardio:ct-nct03436693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03436693](<https://clinicaltrials.gov/study/NCT03436693>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03436693

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

## Technical summary

Registry record NCT03436693. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-15 (actual); primary completion 2021-01-21 (actual). Results posted on 2024-07-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 308 participants (enrolled count; ClinicalTrials.gov record NCT03436693, source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)
- Started: 2018-02-15 (actual) (ClinicalTrials.gov record NCT03436693, source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)
- Primary completion: 2021-01-21 (actual) (ClinicalTrials.gov record NCT03436693, source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)
- Completion: 2021-01-21 (actual) (ClinicalTrials.gov record NCT03436693, source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)
- Results first posted: 2024-07-15 (ClinicalTrials.gov record NCT03436693, source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03436693, source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03436693-2026-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
- Condition: Diabetic Nephropathy
- Intervention (Drug): Canagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Tanabe Pharma Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Tanabe Pharma Corporation (`cardio:org-tanabe-pharma-corporation`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan (`cardio:pubmed-35861630`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3007168f9a17290f860a77c4eec71c5a4abd582bad3da0c76924a80fe05641a5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
